Authors
Latest:
Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsExperts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
Latest:
Niraparib/Dostarlimab/Chemo Improves PFS Vs SOC in Advanced Ovarian CancerNiraparib/dostarlimab with platinum-therapy met its PFS end point in patients with advanced ovarian cancer in the phase 3 FIRST-ENGOT-OV44 trial.
Latest:
Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional FractionationABSTRACT Symptomatic spinal metastasis is a frequent complication of cancer that had been treated, until relatively recently, with primitive techniques to modest radiation dose levels, with a baseline assumption of limited survival and poor patient performance in that setting. In the era of targeted and personalized therapies, many patients are living longer and more functionally and are able to manage their disease on the model of chronic illness. Given these developments, an attractive option is the use of stereotactic body radiation therapy (SBRT) to deliver high biologically effective doses of radiation conformally to maximize the palliative gains of treatment. However, randomized data to guide practice are scarce. We review the extant literature and present an algorithmic approach to selecting patients with metastatic disease for palliative spinal SBRT favoring the results of available randomized studies and remaining within the safety constraints supported by evidence from randomized trials.
Latest:
Survival of Patients With Inoperable Non–Small Cell Lung Cancer With Baseline Severe Pulmonary Dysfunction: Impacts of Thoracic Radiotherapy and Predictive Analysis for Acute Radiation PneumonitisQianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.
Latest:
Brief Overview of Therapeutic Landscape for R/R MMPanelists discuss how emerging therapies like bispecific antibodies, chimeric antigen receptor (CAR) T cells, and novel drug combinations are reshaping treatment options for patients with relapsed/refractory multiple myeloma (R/R MM) who have exhausted standard approaches.
Latest:
How to Treat Metastatic Malignant Triton Tumor in an AdolescentA systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Latest:
Ponatinib-Related Toxicity Management in ALL/CML Improves Over TimeFrom 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.
Latest:
Clinical Pearls on Recent Advances and the Future of Treatment in RCCMehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.
Latest:
Unmet Needs and Future Directions in the Management of Multiple MyelomaExperts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
Value of Collaboration in Managing Patients With Metastatic RCCClosing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.
Latest:
Stéphane Champiat, MD, PhD, Talks Benefits With and Next Steps for SOT101 and PembrolizumabStéphane Champiat, MD, PhD, spoke about the reasoning behind using the IL-2/IL-15 superagonist SOT101 and where the research is heading for patients with solid tumors.
Latest:
Yelena Y. Janjigian, MD, Reviews MSI as a Biomarker in for Localized Gastric CancerYelena Y. Janjigian, MD, spoke about which biomarkers were most predictive for treatment of localized gastric cancer.
Latest:
Between the Lines™ Podcast: Incorporating Real-World Evidence into Clinical Decisions in NSCLCLyudmila Bazhenova, MD, and Federico Albrecht, MD, detailed the importance of using real-world evidence to inform treatment for patients with EGFR-mutated non–small cell lung cancer.
Latest:
A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity ReactionStacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.
Latest:
Strategies For Management of InfectionsPanelists discuss how any patient receiving a bispecific antibody should be given IVIG for their hypogammaglobulinemia and patients should be treated with this monthly for the first 6 months of treatment.
Latest:
Unmet Needs and Future Directions in the Management of Multiple MyelomaExperts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.
